IRIS
ELENA, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.243
AS - Asia 1.769
EU - Europa 1.331
SA - Sud America 254
AF - Africa 57
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 5
Totale 5.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.173
CN - Cina 784
SG - Singapore 380
IE - Irlanda 377
HK - Hong Kong 236
BR - Brasile 177
VN - Vietnam 173
RU - Federazione Russa 160
FI - Finlandia 150
DE - Germania 143
IT - Italia 109
UA - Ucraina 95
FR - Francia 87
GB - Regno Unito 66
SE - Svezia 43
CA - Canada 38
IN - India 36
AR - Argentina 32
MX - Messico 22
ZA - Sudafrica 20
BD - Bangladesh 19
BE - Belgio 18
IQ - Iraq 18
NL - Olanda 18
TR - Turchia 18
PL - Polonia 16
ES - Italia 13
JP - Giappone 13
PK - Pakistan 13
MA - Marocco 11
AT - Austria 10
CL - Cile 10
CO - Colombia 10
ID - Indonesia 9
VE - Venezuela 9
EC - Ecuador 8
SA - Arabia Saudita 8
AU - Australia 7
AZ - Azerbaigian 6
LT - Lituania 6
PY - Paraguay 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
LB - Libano 5
PH - Filippine 5
EG - Egitto 4
IL - Israele 4
JO - Giordania 4
KR - Corea 4
TN - Tunisia 4
AM - Armenia 3
CZ - Repubblica Ceca 3
EU - Europa 3
GR - Grecia 3
KE - Kenya 3
NP - Nepal 3
OM - Oman 3
BY - Bielorussia 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RO - Romania 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AO - Angola 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
CH - Svizzera 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
JM - Giamaica 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MQ - Martinica 1
MU - Mauritius 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
QA - Qatar 1
RS - Serbia 1
UY - Uruguay 1
Totale 5.668
Salva come PNG Salva come JPEG
Città #
Dublin 377
Chandler 232
Hong Kong 229
Ashburn 206
San Jose 201
Dallas 197
Singapore 191
Nanjing 163
Jacksonville 145
Beijing 137
Boardman 110
Ho Chi Minh City 70
Nanchang 67
Ann Arbor 63
Princeton 58
Los Angeles 57
Lauterbourg 56
Lawrence 56
Medford 54
Changsha 53
New York 50
Wilmington 50
Helsinki 48
Hanoi 39
Hebei 38
Jiaxing 37
Shenyang 36
Munich 34
Pavia 31
Redondo Beach 26
Shanghai 25
Buffalo 24
Moscow 24
Orem 23
Hangzhou 22
Turku 21
Milan 19
Toronto 19
Brussels 18
São Paulo 18
Johannesburg 17
Santa Clara 16
Tianjin 15
Belo Horizonte 13
Chennai 13
Montreal 13
Warsaw 13
Atlanta 12
Norwalk 12
Woodbridge 12
Frankfurt am Main 11
Houston 11
London 11
San Francisco 11
Seattle 11
Denver 10
Tokyo 10
Brooklyn 9
Chicago 9
Mexico City 9
Nuremberg 9
Haiphong 8
Jinan 8
Manchester 8
The Dalles 8
Ankara 7
Guangzhou 7
Vienna 7
Baghdad 6
Da Nang 6
Washington 6
Amsterdam 5
Boston 5
Bến Tre 5
Columbus 5
Fairfield 5
Falkenstein 5
Falls Church 5
Istanbul 5
Kunming 5
Phoenix 5
Pune 5
Stockholm 5
Tashkent 5
Verona 5
Amman 4
Asunción 4
Baku 4
Campinas 4
Casablanca 4
Charlotte 4
City of London 4
Hải Dương 4
Karbala 4
Lahore 4
Ningbo 4
Poplar 4
Riyadh 4
Taizhou 4
Zhengzhou 4
Totale 3.772
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 185
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 178
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 142
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 141
Blast phase of essential thrombocythemia: A single center study. 137
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 137
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 134
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 129
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 125
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 122
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia 118
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 115
Clinical significance of somatic mutation in unexplained blood cytopenia 115
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 114
Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms 114
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 113
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes 110
Relationship between clone metrics and clinical outcome in clonal cytopenia 104
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 104
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 103
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications 101
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 100
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 98
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 95
Somatic mutations of calreticulin in myeloproliferative neoplasms 95
Incidence and Prognosis of Clonal Hematopoiesis in patients with Chronic Idiopathic Neutropenia 95
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 91
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 91
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 90
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 90
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 89
Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications 85
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 84
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 84
‘Real-life’ study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis 84
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 83
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 82
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 81
Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis 81
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 81
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 80
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 79
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 79
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions 79
Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia 78
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification 75
Mutational status of myeloproliferative neoplasms. 74
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 73
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis 73
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 72
A cross‐sectional study on quality of life in adult indolent systemic mastocytosis and its association with cutaneous involvement 71
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 70
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. 69
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 66
Validation of cytogenetic-based risk stratification in primary myelofibrosis. 57
Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry 57
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. 56
The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. 53
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem? 51
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry 48
Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series 42
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 40
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry 38
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis 31
Unusual widespread cutaneous eruption due to nilotinib therapy for chronic myeloid leukemia 16
Totale 5.847
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.927
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.927
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202164 0 0 0 0 0 0 0 0 0 32 21 11
2021/2022289 5 3 3 6 5 7 4 16 13 21 40 166
2022/2023836 77 60 5 43 80 61 0 38 423 6 30 13
2023/2024368 53 59 21 23 27 100 1 29 3 5 8 39
2024/2025947 22 71 26 21 28 63 62 67 211 34 126 216
2025/20262.172 152 204 283 284 252 90 441 74 233 159 0 0
Totale 5.847